Fractyl Labs touts improved glycemic control in Type II patient w/DMR treatment
Fractyl Laboratories today presented data from a trial of its Revita DMRTM system designed for minimally invasive duodenal mucosal resurfacing procedures to treat metabolic diseases, touting improved glycemic control in type II diabetes patients along with other benefits.
Data from a 1st-in-human study of 39 patients reported that after 6 months, patients who received the company’s proprietary DMR treatment showed improvements in fasting glucose and HbA1c, lowered hepatic transaminase levels and lowering HOMA-IR.
“Over the last 2 months, we have had the opportunity to present to and learn from different specialties across the disciplines that treat and study the major metabolic diseases. We believe we are developing an intervention that can reverse a critical pathological defect that is a driver of multiple metabolic conditions,” CEO Dr. Harith Rajagopalan said in a press release.
The company said another 50-patient trial of its DMR system is underway, having enrolled 28 patients so far across European sites.
“This presentation of 1st-in-human data is the most comprehensive look we have thus far at the potential impact that duodenal resurfacing can have on insulin resistance and metabolic diseases, including type 2 diabetes. This is a very interesting time to be working in the field of metabolic diseases. The new guidelines published last month recommending that bariatric surgery be considered as a treatment for type 2 diabetes patients with inadequate blood glucose control are an historic change. Given the scale of the diabetes and liver epidemics, however, we need to explore less invasive approaches,” Alan Cherrington of Vanderbilt University said in a prepared statement.